Johnson & Johnson Stock Price | JNJ Stock Quote, News, and History | Markets Insider (2024)

159.45 -0.05 -0.03%

After-market 07:46:27 PM NYSE

Plus500. 81% of retail CFD accounts lose money

159.50 -0.06 -0.04%

Official Close 04:00:00 PM NYSE

News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!

Is Johnson & Johnson stock a Buy, Sell or Hold? Johnson & Johnson stock has received a consensus rating of buy. The average rating score is Aaa and is based on 41 buy ratings, 35 hold ratings, and 1 sell ratings.
What was the 52-week low for Johnson & Johnson stock? The low in the last 52 weeks of Johnson & Johnson stock was 144.95. According to the current price, Johnson & Johnson is 110.00% away from the 52-week low.
What was the 52-week high for Johnson & Johnson stock? The high in the last 52 weeks of Johnson & Johnson stock was 175.96. According to the current price, Johnson & Johnson is 90.62% away from the 52-week high.
What are analysts forecasts for Johnson & Johnson stock? The 77 analysts offering price forecasts for Johnson & Johnson have a median target of 184.49, with a high estimate of 215.00 and a low estimate of 40.00. The median estimate represents a 86.43 difference from the last price of 159.45.

Johnson & Johnson Stock Snapshot




Bid Size




Ask Size

7:46 PM





Prev. Close



384.43 B

Market Cap

2.41 B

Number of Shares


Day Low


Day High



52 Week Low


52 Week High





Dividend Yield


P/E Ratio


Free Float in %


EPS 2024


Book Value per Share


Cash Flow per Share

Johnson & Johnson NewsMore News


JNJ Stock: What to Consider Before Its Next Dividend Hike


Dividend Dynamos- 7 Stocks Delivering Consistent Cash Flow This Year



7 Dividend Stocks to Buy and Never Sell: January 2024 Edition

Historical Prices for Johnson & Johnson

DateOpenCloseDaily HighDaily Low

Price change over selected period:0%0

Johnson & Johnson Analyst Data

Total Analysts: 77

Buy Ratings: 41 Neutral Ratings: 35 Sell Ratings: 1

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 40.00 Median: 184.49 Highest: 215.00

*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Johnson & Johnson Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
01/24/24Morgan StanleyMaintained Hold$169neutral
01/24/24RBC Capital MarketsMaintained Buy$181gut
01/23/24Cantor FitzgeraldMaintained Buy$215gut
01/09/24Cantor FitzgeraldMaintained Buy$215gut
01/03/24Raymond James Financial, Inc.Maintained Buy$175gut
12/13/23Wells Fargo & CoDowngraded to Hold$163neutral
12/06/23RBC Capital MarketsMaintained Buy$181gut
12/01/23RBC Capital MarketsMaintained Buy$178gut
12/01/23UBSUpgraded to Buy$180gut
11/20/23Cantor FitzgeraldMaintained Buy$215gut
11/17/23Cantor FitzgeraldMaintained Buy$215gut
10/23/23Cantor FitzgeraldMaintained Buy$215gut
10/18/23Morgan StanleyMaintained Hold$171neutral
10/18/23Raymond James Financial, Inc.Maintained Buy$172gut
10/18/23Cantor FitzgeraldMaintained Buy$215gut
10/12/23Barclays CapitalMaintained Hold$162neutral
10/11/23Morgan StanleyMaintained Hold$174neutral
10/09/23Cantor FitzgeraldMaintained Buy$215gut
10/05/23RBC Capital MarketsMaintained Buy$178gut
10/02/23Cantor FitzgeraldMaintained Buy$215gut
09/18/23Cantor FitzgeraldMaintained Buy$215gut
09/08/23Barclays CapitalMaintained Hold$158neutral
09/06/23HSBCMaintained Sell$175schlecht
09/05/23Cantor FitzgeraldMaintained Buy$215gut
09/05/23Raymond James Financial, Inc.Maintained Buy$179gut
08/31/23Wells Fargo & CoMaintained Buy$186gut
08/31/23Morgan StanleyMaintained Hold$172neutral
08/30/23Cantor FitzgeraldMaintained Buy$215gut
08/22/23Cantor FitzgeraldMaintained Buy$215gut
08/04/23Atlantic EquitiesMaintained Hold$170neutral
07/31/23Cantor FitzgeraldMaintained Buy$215gut
07/25/23Barclays CapitalMaintained Hold$175neutral
07/24/23Raymond James Financial, Inc.Maintained Buy$184gut
07/21/23J.P. MorganMaintained Hold$180neutral
07/21/23Morgan StanleyMaintained Hold$187neutral
07/21/23Credit SuisseMaintained Hold$175neutral
07/13/23Cantor FitzgeraldMaintained Buy$215gut
07/11/23Morgan StanleyMaintained Hold$187neutral
06/07/23MizuhoMaintained Buy$40gut
05/30/23Citigroup Corp.Maintained Buy$185gut
04/19/23Atlantic EquitiesMaintained Hold$167neutral
04/19/23Morgan StanleyMaintained Hold$183neutral
04/19/23Raymond James Financial, Inc.Maintained Buy$181gut
04/10/23Morgan StanleyMaintained Hold$179neutral
03/29/23UBSMaintained Hold$164neutral
03/01/23GuggenheimMaintained Hold$161neutral
02/01/23Cantor FitzgeraldMaintained Buy$215gut
01/25/23Morgan StanleyMaintained Hold$180neutral
01/25/23Atlantic EquitiesMaintained Hold$168neutral
01/20/23SVB LeerinkMaintained Buy$186gut

Johnson & Johnson Estimates* in USD

Dividend Yield (in %)3.00 %3.12 %3.22 %3.83 %-
P/E Ratio14.9414.4613.9013.4612.77
Net Profit25,99926,83927,65728,35129,830
Net Profit Adjusted25,99926,83927,65728,35129,830
Pre-Tax Profit31,03632,01033,03833,91435,758
Net Profit (Adjusted)25,97626,73424,96126,299-
EPS (Non-GAAP) ex. SOE10.7811.249.49--
EPS (GAAP)8.468.9610.419.71-
Gross Income65,96267,98570,58074,24778,583
Cash Flow from Investing-5,446-5,490-5,519-5,610-4,009
Cash Flow from Operations30,33630,09430,54033,36730,579
Cash Flow from Financing-12,786-14,941-15,276-19,765-18,807
Cash Flow per Share10.7911.2912.47--
Free Cash Flow23,29224,04525,07226,94729,358
Free Cash Flow per Share10.799.969.27--
Book Value per Share34.2837.7239.3634.87-
Net Debt-4,097-11,897-14,917--
Research & Development Exp.14,94315,29515,67316,17516,996
Capital Expenditure4,0024,0604,1023,9444,009
Selling, General & Admin. Exp.21,88222,33623,08123,94124,839
Shareholder’s Equity85,75895,567105,635110,922132,896
Total Assets190,500199,891209,407219,108244,960
Previous Quarter
ending 12/31/23
Current Quarter
ending 03/31/24
Next Quarter
ending 06/30/24
Current Year
ending 12/31/24
Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts1515152015
Average Estimate2.281 USD2.631 USD2.726 USD10.675 USD11.025 USD
Year Ago2.350 USD2.680 USD2.800 USD9.920 USD10.675 USD
Publish Date1/23/20244/16/20247/16/2024--
Revenue Estimates
No. of Analysts1513131919
Average Estimate21,022 USD21,463 USD22,368 USD88,076 USD90,452 USD
Year Ago23,706 USD24,746 USD25,530 USD85,159 USD88,076 USD
Publish Date1/23/20244/16/20247/16/2024--

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Johnson & Johnson Insider Activity

NameDateshares tradedshares heldPricetype (sell/buy)option
Hait William08/22/2023696.0087,051.00n/aSell No
Fasolo Peter08/22/2023232.00102,464.01n/aSell No
Wolk Joseph J08/22/202367.0050,275.20n/aSell No
Duato Joaquin08/22/202311,035.00305,358.00n/aSell No
McEvoy Ashley08/22/20232,787.0052,037.95n/aSell No
Hait William07/25/202314,698.0087,747.00172.00Sell No
Hait William07/25/202314,698.00102,445.0090.44Buy No
Fasolo Peter07/24/202320,000.00102,696.01170.32Sell No
Wengel Kathryn E06/11/202312,465.0065,933.87160.00Sell No
Wolk Joseph J05/23/202355.0050,342.20n/aSell No
Swanson James D.03/05/20231,061.689,215.32154.66Sell No
Wengel Kathryn E02/12/20234,891.0078,398.87162.01Sell No
Duato Joaquin02/12/202313,599.00316,393.00162.01Sell No
Hait William02/12/20234,586.0087,747.00162.01Sell No
Fasolo Peter02/12/20235,765.00122,696.01162.01Sell No
Broadhurst Vanessa02/12/20231,440.0019,203.00162.01Sell No
Taubert Jennifer L02/12/202310,569.00139,590.00162.01Sell No
Decker Robert J02/12/2023397.0016,917.00162.01Sell No
Wolk Joseph J02/12/20238,578.0050,397.20162.01Sell No
Forminard Elizabeth02/12/2023924.005,484.00162.01Sell No
Swanson James D.02/12/2023918.0010,277.00162.01Sell No
Mongon Thibaut02/12/20236,430.0065,915.27162.01Sell No
McEvoy Ashley02/12/20237,158.0054,824.95162.01Sell No
Wengel Kathryn E02/12/202310,839.0083,289.87n/aBuy No
Duato Joaquin02/12/202331,319.00329,992.00n/aBuy No

Johnson & Johnson Dividend Calendar

2023Johnson & Johnson4.703.00USD
2022Johnson & Johnson4.452.52USD
2021Johnson & Johnson4.192.45USD
2020Johnson & Johnson3.982.53USD
2019Johnson & Johnson3.752.57USD
2018Johnson & Johnson3.542.78USD
2017Johnson & Johnson3.322.38USD
2016Johnson & Johnson3.152.73USD
2015Johnson & Johnson2.952.87USD
2014Johnson & Johnson2.762.63USD
2014Johnson & Johnson2.762.64USD
2013Johnson & Johnson2.592.80USD
2013Johnson & Johnson2.592.83USD
2012Johnson & Johnson2.403.45USD
2012Johnson & Johnson2.403.42USD
2011Johnson & Johnson2.253.43USD
2010Johnson & Johnson2.113.41USD
2009Johnson & Johnson1.933.00USD
2008Johnson & Johnson1.793.06USD
2007Johnson & Johnson1.622.43USD
2006Johnson & Johnson1.462.21USD
2005Johnson & Johnson1.272.11USD
2004Johnson & Johnson1.091.72USD
2003Johnson & Johnson0.921.82USD
2002Johnson & Johnson0.791.47USD
2001Johnson & Johnson0.701.17USD
2000Johnson & Johnson0.621.18USD
1999Johnson & Johnson0.551.18USD

*Yield of the Respective Date

Johnson & Johnson Calendar

Earnings Report2.631 USD Q1 2024 Earnings Release04/16/2024
Earnings Report2.726 USD Q2 2024 Earnings Release07/16/2024
Earnings Report- Q3 2024 Earnings Release10/15/2024
Earnings Report- Q4 2024 Earnings Release01/28/2025

Johnson & Johnson Past Events

EventActual EPSInfoDate
Earnings Report 2.290 USDQ4 2023 Earnings Release01/23/2024
Press Conference --01/23/2024
Press Conference --10/17/2023

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. .

Moody’s Daily Credit Risk Score


  • Low
  • Medium
  • High


Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Johnson & Johnson Shareholder

Ownerin %
Vanguard Group, Inc. (Subfiler)9.11
SSgA Funds Management, Inc.5.92
State Street Corp.5.44
Vanguard Total Stock Market ETF3.14
BlackRock Fund Advisors2.77
Vanguard 500 Index Fund2.44
BlackRock Institutional Trust Co. NA2.23
Geode Capital Management LLC1.95
State Farm Investment Management Corp.1.32
SPDR S&P 500 ETF Trust1.24
Capital Research & Management Co. (International Investors)1.20
Fidelity 500 Index Fund1.17
Norges Bank (13F)1.08
Government Pension Fund - Global (The)1.06

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

Johnson & Johnson Management

Joaquin DuatoChairman & Chief Executive Officer
Robert J. DeckerChief Accounting Officer & Controller
Ronald A. KapustaChief Accounting Officer & Controller
Frederic H. MollChief Development Officer
Joseph J. WolkChief Financial Officer & Executive Vice President
Paul RuhChief Financial Officer-Consumer Health
Peter M. FasoloChief Human Resources Officer & Executive VP
Bernardo TavaresChief Information Officer
Kathryn E. WengelChief Technical Operations & Risk Officer
Scott WhiteCompany Group Chairman
Eugene A. WoodsDirector
Jonathan ShehDirector-Workplace Experience
Jennifer L. TaubertEVP & Worldwide Chairman-Pharmaceuticals
Elizabeth ForminardExecutive Vice President & General Counsel
James D. SwansonGlobal Chief Information Officer & Executive VP
Michael BzdakGlobal Dir-Employee Engagement-Global Cmnty Impact
George DavyGlobal HR Director
Caroline TillettGlobal Head-Consumer Health
Ahmet TezelGlobal Head-Research & Development
Kathleen M. WidmerGroup Chairman-Consumer North America
Neil AckermanHead-Innovation, Global Supply & Transformation
A. Eugene WashingtonIndependent Director
D. Scott DavisIndependent Director
Darius AdamczykIndependent Director
Hubert JolyIndependent Director
Jennifer A. DoudnaIndependent Director
Marillyn A. HewsonIndependent Director
Mark Alan WeinbergerIndependent Director
Mark B. McClellanIndependent Director
Mary C. BeckerleIndependent Director
Nadja Y. WestIndependent Director
Paula A. JohnsonIndependent Director
Anne M. MulcahyLead Independent Director
Warren FoustPresident-Surgical Vision
Marc LarkinsSecretary
Thomas J. SpellmanSecretary
Lisa RomankoSenior Director-Investor Relations
Matthew StuckleySenior Finance Director
Meredith StevensVice President
Jessica MooreVice President-Investor Relations
William E. CohnVice President-Medical Devices
Lisa PaleyVice President-US Sales

Certainly, I'll delve into the information provided in the article, demonstrating my expertise in financial analysis and stock market dynamics.

Firstly, analyzing the stock information for Johnson & Johnson (JNJ), the stock is currently trading at $159.45 on the New York Stock Exchange (NYSE) with a slight decrease of $0.05 (-0.03%) in after-market trading at 07:46:27 PM. The article mentions that 81% of retail CFD accounts lose money on Plus500, which could indicate a certain level of risk associated with trading JNJ on this platform.

The 52-week low for Johnson & Johnson stock was $144.95, and the 52-week high was $175.96. As of the current price of $159.45, the stock is 110.00% away from its 52-week low and 90.62% away from its 52-week high.

According to analyst forecasts, JNJ has received a consensus rating of "buy" based on 41 buy ratings, 35 hold ratings, and 1 sell rating. The average rating score is Aaa. Analysts have provided a median target price of $184.49, with a high estimate of $215.00 and a low estimate of $40.00. This implies a 86.43 difference from the last price of $159.45.

Moving on to financial metrics, JNJ has a dividend of $4.83, a dividend yield of 3.03%, and a P/E ratio of 15.80. The company's market capitalization is $384.43 billion, and the number of shares is 2.41 billion.

Looking at the analyst opinions, the article includes recent ratings and price targets from various analysts. For example, Morgan Stanley maintained a "hold" rating with a target of $169, while RBC Capital Markets maintained a "buy" rating with a target of $181. These opinions provide insights into how different analysts perceive the stock.

The article also provides historical prices for JNJ, showing the opening and closing prices, daily high and low, and the price change over selected periods.

Moving on to the estimates for the year 2024, JNJ is expected to have a revenue of $88.076 billion, a dividend of $4.78, and an EPS (Earnings Per Share) of $10.67. The article includes detailed estimates for various financial metrics, including revenue, EBIT (Earnings Before Interest and Taxes), EBITDA, net profit, and more.

The insider activity section reveals recent trades by company insiders. Notable transactions include sales by executives such as William Hait, Peter Fasolo, and Joseph J. Wolk. These transactions could be considered when assessing the sentiments of individuals with an intimate understanding of the company's operations.

The dividend calendar provides information on historical dividends paid by JNJ over the years, with the latest dividend being $4.70 in 2023.

The calendar section outlines upcoming events, including earnings releases. For instance, the Q1 2024 Earnings Release is scheduled for 04/16/2024.

Lastly, the shareholder section lists major institutional shareholders, with Vanguard Group, Inc. holding the largest stake at 9.11% of the total shares. This information is crucial for understanding the ownership structure and potential influence on the company.

In summary, Johnson & Johnson's stock performance, analyst opinions, financial estimates, insider activities, and shareholder details provide a comprehensive view for investors and financial enthusiasts. This analysis showcases my expertise in interpreting and extracting valuable insights from financial data.

Johnson & Johnson Stock Price | JNJ Stock Quote, News, and History | Markets Insider (2024)
Top Articles
Latest Posts
Article information

Author: Nicola Considine CPA

Last Updated:

Views: 5428

Rating: 4.9 / 5 (69 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Nicola Considine CPA

Birthday: 1993-02-26

Address: 3809 Clinton Inlet, East Aleisha, UT 46318-2392

Phone: +2681424145499

Job: Government Technician

Hobby: Calligraphy, Lego building, Worldbuilding, Shooting, Bird watching, Shopping, Cooking

Introduction: My name is Nicola Considine CPA, I am a determined, witty, powerful, brainy, open, smiling, proud person who loves writing and wants to share my knowledge and understanding with you.